Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)
Public ClinicalTrials.gov record NCT01730053. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin Versus Ezetimibe Added-on to Rosuvastatin Versus Rosuvastatin Dose Increase in Patients Who Are Not Controlled on Rosuvastatin
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab (REGN727/SAR236553) as an add-on therapy to other LMT in patients with hypercholesterolemia at high cardiovascular (CV) risk.
Study identification
- NCT ID
- NCT01730053
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 305 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2012 (Actual)
- Primary completion
- Apr 30, 2014 (Actual)
- Completion
- May 31, 2014 (Actual)
- Last update posted
- Apr 7, 2020
2012 – 2014
United States locations
- U.S. sites
- 54
- U.S. states
- 23
- U.S. cities
- 54
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Chandler | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Anaheim | California | — | — |
| Not listed | Beverly Hills | California | — | — |
| Not listed | Fair Oaks | California | — | — |
| Not listed | Newport Beach | California | — | — |
| Not listed | Northridge | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | Walnut Creek | California | — | — |
| Not listed | Milford | Connecticut | — | — |
| Not listed | Atlantis | Florida | — | — |
| Not listed | Bradenton | Florida | — | — |
| Not listed | Clearwater | Florida | — | — |
| Not listed | Fort Lauderdale | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Lakeland | Florida | — | — |
| (2 Locations) | Miami | Florida | — | — |
| Not listed | Oviedo | Florida | — | — |
| Not listed | Pinellas Park | Florida | — | — |
| Not listed | Port Orange | Florida | — | — |
| Not listed | Sarasota | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | West Palm Beach | Florida | — | — |
| Not listed | Winter Park | Florida | — | — |
| Not listed | Boise | Idaho | — | — |
| Not listed | Morton | Illinois | — | — |
| Not listed | Evansville | Indiana | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Newton | Kansas | — | — |
| Not listed | Overland Park | Kansas | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Auburn | Maine | — | — |
| Not listed | Bethesda | Maryland | — | — |
| Not listed | Edina | Minnesota | — | — |
| Not listed | Rochester | Minnesota | — | — |
| Not listed | Olive Branch | Mississippi | — | — |
| Not listed | Port Gibson | Mississippi | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Butte | Montana | — | — |
| Not listed | Williamsville | New York | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Marion | Ohio | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Warwick | Rhode Island | — | — |
| Not listed | Greer | South Carolina | — | — |
| Not listed | Summerville | South Carolina | — | — |
| Not listed | Kingsport | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Bountiful | Utah | — | — |
| Not listed | Salt Lake City | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01730053, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 7, 2020 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01730053 live on ClinicalTrials.gov.